These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 37008199)
1. Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles (Nanps) via Spatial Arrangement of Their Therapeutic Moieties. Chandler M; Rolband L; Johnson MB; Shi D; Avila YI; Cedrone E; Beasock D; Danai L; Stassenko E; Krueger JK; Jiang J; Lee JS; Dobrovolskaia MA; Afonin KA Adv Funct Mater; 2022 Oct; 32(43):. PubMed ID: 37008199 [TBL] [Abstract][Full Text] [Related]
2. Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles. Hong E; Halman JR; Shah AB; Khisamutdinov EF; Dobrovolskaia MA; Afonin KA Nano Lett; 2018 Jul; 18(7):4309-4321. PubMed ID: 29894623 [TBL] [Abstract][Full Text] [Related]
3. Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior. Chandler M; Afonin KA Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 31013847 [TBL] [Abstract][Full Text] [Related]
4. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution. Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854 [TBL] [Abstract][Full Text] [Related]
5. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Ke W; Afonin KA Adv Drug Deliv Rev; 2021 Sep; 176():113835. PubMed ID: 34144087 [TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells. Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721 [TBL] [Abstract][Full Text] [Related]
7. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs). Nordmeier S; Ke W; Afonin KA; Portnoy V Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137 [TBL] [Abstract][Full Text] [Related]
8. Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights. Rebolledo LP; Ke W; Cedrone E; Wang J; Majithia K; Johnson MB; Dokholyan NV; Dobrovolskaia MA; Afonin KA ACS Appl Mater Interfaces; 2024 Feb; 16(7):8430-8441. PubMed ID: 38344840 [TBL] [Abstract][Full Text] [Related]
9. The immunorecognition, subcellular compartmentalization, and physicochemical properties of nucleic acid nanoparticles can be controlled by composition modification. Johnson MB; Halman JR; Miller DK; Cooper JS; Khisamutdinov EF; Marriott I; Afonin KA Nucleic Acids Res; 2020 Nov; 48(20):11785-11798. PubMed ID: 33091133 [TBL] [Abstract][Full Text] [Related]
10. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786 [TBL] [Abstract][Full Text] [Related]
11. Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology. Afonin KA; Dobrovolskaia MA; Church G; Bathe M ACS Nano; 2020 Aug; 14(8):9221-9227. PubMed ID: 32706238 [TBL] [Abstract][Full Text] [Related]
12. The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells. Bila D; Radwan Y; Dobrovolskaia MA; Panigaj M; Afonin KA Molecules; 2021 Jul; 26(14):. PubMed ID: 34299506 [TBL] [Abstract][Full Text] [Related]
13. Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro. Juneja R; Vadarevu H; Halman J; Tarannum M; Rackley L; Dobbs J; Marquez J; Chandler M; Afonin K; Vivero-Escoto JL ACS Appl Mater Interfaces; 2020 Sep; 12(35):38873-38886. PubMed ID: 32805923 [TBL] [Abstract][Full Text] [Related]
14. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles. Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles. Panigaj M; Skelly E; Beasock D; Marriott I; Johnson MB; Salotti J; Afonin KA Front Immunol; 2023; 14():1053550. PubMed ID: 36798121 [TBL] [Abstract][Full Text] [Related]
16. Break to Build: Isothermal Assembly of Nucleic Acid Nanoparticles (NANPs) Beasock D; Ha A; Halman J; Panigaj M; Wang J; Dokholyan NV; Afonin KA Bioconjug Chem; 2023 Jun; 34(6):1139-1146. PubMed ID: 37293781 [TBL] [Abstract][Full Text] [Related]
17. Change in Lipofectamine Carrier as a Tool to Fine-Tune Immunostimulation of Nucleic Acid Nanoparticles. Newton HS; Radwan Y; Xu J; Clogston JD; Dobrovolskaia MA; Afonin KA Molecules; 2023 Jun; 28(11):. PubMed ID: 37298960 [TBL] [Abstract][Full Text] [Related]